Erector Spinae Plane Block in Post-herpetic Neuralgia
Status:
Completed
Trial end date:
2021-06-19
Target enrollment:
Participant gender:
Summary
This randomized clinical study will be carried out on 72 patients admitted to the pain clinic
in Tanta University Hospitals with post-herpetic neuralgia.
Cases presenting to the Pain Clinic with acute pain due to postherpetic neuralgia in thoracic
and/or lumbar dermatomes with numerical rating scale (NRS) of 6 or more and they will be
randomly divided, using the closed envelop method, into three equal groups.
Group A (24 patients): Patients will be subjected to the routine medical treatment of post
herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol) and sham erector
spinae plane block Group B (24 patients): Patients will be subjected to erector spinae block
by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose) together with medical
treatment.
Group C (24 patients): Patients that will subjected to erector spinae block by bupivacaine (2
- 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg))
together with medical treatment.
Primary outcome will be the efficacy of pain relief Secondary outcome will be the frequency
of pain and the consumption of analgesics.